UNSPSC 51132203: Acetaminophen/aluminum hydroxide/aspirin/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132203 Acetaminophen/aluminum hydroxide/aspirin/salicylamide, a Commodity code, encompasses state and local procurement of over-the-counter analgesic and antipyretic products, though recent solicitations tagged under this code show significant scope divergence. State and local bodies are acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and OTC products through cooperative purchasing and direct procurement channels. The issuing bodies span county health departments, state health agencies, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Department of Administration (operating the MMCAP cooperative) appear as active buyers in the recent record.

Recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) targeting distribution across participating state and local government facilities in Minnesota and Oregon through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs. The geographic spread includes Florida, Texas, Minnesota, and Oregon. Vendors responding to MMCAP must maintain relationships with at least two of three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.